不同剂量重组组织纤溶酶原激活剂静脉溶栓对急性脑梗死后凝血指标的影响

被引：6

作者：

孙旭红 ^{[1
]}

Paul Trouillas ^{[2
]}

Michel Bertiller ^{[2
]}

Michel Hanss ^{[2
]}

李威 ^{[1
]}

刘建仁 ^{[1
]}

机构：

[1] 上海交通大学医学院附属上海市第九人民医院神经内科

[2] 法国里昂神经科医院脑血管病科

来源：

蚌埠医学院学报 | 2013年 / 38卷 / 06期

关键词：

脑梗死; 溶栓治疗; 重组组织纤溶酶原激活物; 凝血指标;

D O I：

10.13898/j.cnki.issn.1000-2200.2013.06.042

中图分类号：

R743.33 [脑栓塞];

学科分类号：

1002 ;

摘要：

目的:观察不同剂量重组组织纤溶酶原激活剂(rt-PA)对急性脑梗死静脉溶栓后纤维蛋白原、纤维蛋白降解产物、D-二聚体等凝血指标的影响。方法:选择80例发病后7 h静脉溶栓的急性大脑中动脉供血区脑梗死患者,随机分为rt-PA 0.8 mg/kg和0.9 mg/kg静脉溶栓治疗组各40例。分别在溶栓前、溶栓后2 h,溶栓后24 h静脉采血,观察2组纤维蛋白原、纤维蛋白溶解产物、D-二聚体、凝血因子ⅩⅢ、α2-抗纤溶酶、纤溶酶原和血小板水平。结果:rt-PA 0.8 mg/kg组和0.9 mg/kg组患者纤维蛋白原、纤维蛋白溶解产物、D-二聚体、凝血因子ⅩⅢ、α2-抗纤溶酶、纤溶酶原和血小板水平差异均无统计学意义(P>0.05)。结论:rt-PA 0.8 mg/kg组和0.9 mg/kg组患者溶栓后凝血指标均无明显不同;脑梗死患者可考虑推荐使用rt-PA0.8 mg/kg为药物使用的单位计量。

引用

页码：710 / 713

页数：4

共 13 条

[1]

Thrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice: The Japan post-Marketing Alteplase Registration Study (J-MARS)[J] . Jyoji Nakagawara,Kazuo Minematsu,Yasushi Okada,Norio Tanahashi,Shinji Nagahiro,Etsuro Mori,Yukito Shinohara,Takenori Yamaguchi.Stroke . 2010 (9)

[2]

Patients with thrombolysed stroke in Vietnam have an excellent outcome: results from the Vietnam Thrombolysis Registry[J] . T. H.Nguyen,A. L. T.Truong,M. B.Ngo,C. T. Q.Bui,Q. V.Dinh,T. C.Doan,L. T. K.Nguyen,T. C.Phan,M. V.Phan,T. V.Nguyen,T. V.Le.European Journal of Neurology . 2010 (9)

[3] Feasibility and Safety of Intravenous Thrombolysis in Multiethnic Asian Stroke Patients in Singapore [J].

Sharma, Vijay K. ;

Tsivgoulis, Georgios ;

Tan, June H. ;

Wong, Lily Y. H. ;

Ong, Benjamin K. C. ;

Chan, Bernard P. L. ;

Teoh, Hock L. .

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2010, 19 (06) :424-430

[4] Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke [J].

Zhou, Xiao-Yu ;

Wang, Shao-Shi ;

Collins, Marnie L. ;

Davis, Stephen M. ;

Yan, Bernard .

JOURNAL OF CLINICAL NEUROSCIENCE, 2010, 17 (08) :988-992

[5]

Outcomes of Thrombolytic Therapy for Acute Ischemic Stroke in Chinese Patients: The Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study[J] . A-Ching Chao,Hung-Yi Hsu,Chih-Ping Chung,Chung-Hsiang Liu,Chih-Hung Chen,Michael Mu-Huo Teng,Giia-Sheun Peng,Wen-Yung Sheng,Han Hwa Hu.Stroke . 2010 (5)

[6]

Effects of 0.6 mg/kg Intravenous Alteplase on Vascular and Clinical Outcomes in Middle Cerebral Artery Occlusion: Japan Alteplase Clinical Trial II (J-ACT II)[J] . Etsuro Mori,Kazuo Minematsu,Jyoji Nakagawara,Takenori Yamaguchi,Makoto Sasaki,Teruyuki Hirano.Stroke . 2010 (3)

[7] Intravenous Thrombolysis With Low-Dose Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke [J].

Loh, Pei Kee ;

Sharma, Vijay K. .

STROKE, 2010, 41 (03) :E164-E164

[8] Pre-hospital notification reduced the door-to-needle time for iv t-PA in acute ischaemic stroke [J].

Kim, S. K. ;

Lee, S. Y. ;

Bae, H. J. ;

Lee, Y. S. ;

Kim, S. Y. ;

Kang, M. J. ;

Cha, J. K. .

EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (12) :1331-1335

[9]

Hospital resources for urokinase/recombinant tissue-type plasminogen activator therapy for acute stroke in Beijing[J] . Yilong Wang,Di Wu,Xingquan Zhao,Ruihua Ma,Xiangping Guo,Chunxue Wang,Liping Liu,Weijiang Zhao,Yongjun Wang.Surgical Neurology . 2009

[10]

Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of Onset: Japan Alteplase Clinical Trial (J-ACT)[J] . Takenori Yamaguchi,Etsuro Mori,Kazuo Minematsu,Jyoji Nakagawara,Kazuo Hashi,Isamu Saito,Yukito Shinohara.Stroke . 2006 (7)

← 1 2 →